Related Experiment Video

Updated: May 10, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Efficacy of tyrosine kinase inhibitors in routine clinical practice: epidermal growth factor mutations and their

Tanja Ovcaricek1, Tanja Cufer, Izidor Kern

  • 1Department of Pulmonary medicine, University Clinic Maribor, Maribor, Slovenia.

Journal of Cancer Research and Therapeutics
|June 18, 2013
PubMed
Abstract

Insights

EGFR mutation testing in non-small cell lung cancer (NSCLC) reliably identifies patients who benefit from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy, improving progression-free survival.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Activating mutations in the epidermal growth factor (EGFR) gene predict sensitivity to tyrosine kinase inhibitors (TKIs) in advanced non-small cell lung cancer (NSCLC).
  • Evaluating TKI treatment efficacy and the role of EGFR mutations in routine clinical practice is crucial for patient selection.

Purpose of the Study:

  • To assess the efficacy of TKIs in advanced NSCLC patients.
  • To evaluate the implications of EGFR and KRAS mutation status on TKI treatment outcomes.

Main Methods:

  • Retrospective chart review of 40 advanced NSCLC patients treated with TKIs (2005-2010).
  • Analysis of clinicopathological characteristics and mutation status (EGFR, KRAS).
  • Progression-free survival (PFS) and overall survival (OS) estimated using Kaplan-Meier method; log-rank test for differences.

Main Results:

  • EGFR mutations were present in 45% of patients, predominantly exon 19 deletions (55.5%).
  • Significant correlations observed between gender, histology, and EGFR mutations.
  • Median PFS was 8.7 months; median OS not reached.
  • Patients with EGFR mutations showed significantly higher benefit from TKI therapy (mPFS 22.0 vs. 3.2 months) and a trend towards better OS.

Conclusions:

  • EGFR mutation screening is reliable in a routine clinical setting.
  • Mutation testing allows for better selection of NSCLC patients for anti-EGFR TKI therapy.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...